000168122 001__ 168122
000168122 005__ 20240229133557.0
000168122 0247_ $$2doi$$a10.1093/pm/pnaa480
000168122 0247_ $$2pmid$$apmid:33749754
000168122 0247_ $$2ISSN$$a1526-2375
000168122 0247_ $$2ISSN$$a1526-4637
000168122 0247_ $$2altmetric$$aaltmetric:102559930
000168122 037__ $$aDKFZ-2021-00690
000168122 041__ $$aEnglish
000168122 082__ $$a610
000168122 1001_ $$0P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aNguyen, Mai Thi Ngoc$$b0$$eFirst author$$udkfz
000168122 245__ $$aComparison of Five Lists to Identify Potentially Inappropriate Use of Non-Steroidal Anti-Inflammatory Drugs in Older Adults.
000168122 260__ $$aOxford$$bOxford University Press$$c2021
000168122 3367_ $$2DRIVER$$aarticle
000168122 3367_ $$2DataCite$$aOutput Types/Journal article
000168122 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634298539_1826
000168122 3367_ $$2BibTeX$$aARTICLE
000168122 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168122 3367_ $$00$$2EndNote$$aJournal Article
000168122 500__ $$a#EA:C070#LA:C070# / 2021 Sep 8;22(9):1962-1969
000168122 520__ $$aTo compare the prevalence of potentially inappropriate non-steroidal anti-inflammatory drugs (NSAIDs) among NSAIDs users defined with frequently used potentially inappropriate medication (PIM) lists and to identify the determinants of their use.Cross-sectional survey among community-dwelling older adults from Germany.N = 284 NSAIDs users aged 65-89 years.All currently regularly or as-needed used drugs were recorded during a home visit. Multivariate logistic regression models were applied to assess the potential determinants of potentially inappropriate NSAIDs use.Prevalence of potentially inappropriate NSAIDs use was 54.2%, 45.4%, 29.9%, 20.4%, and 3.5% when applying the STOPP, 2019 Beers, EU(7)-PIM, FORTA, and PRISCUS list, respectively. No study participant was identified as a potentially inappropriate NSAIDs user by all five lists simultaneously. The majority (68%) were identified only by one or two lists. Merely the STOPP and Beers criteria had a moderate inter-instrument agreement. Lower pain severity, gout, peptic ulcer (PU), cardiovascular disease (CVD), and chronic kidney disease (CKD) were statistically significantly associated with potentially inappropriate NSAIDs use defined by the STOPP criteria and the latter three conditions also with the 2019 Beers criteria.The STOPP and Beers criteria may be superior to the other lists because they more frequently identify potentially inappropriate NSAIDs use in conditions implying a high risk for NSAIDs' adverse events (i.e., PUD, CKD and CVD). We developed a harmonized, country-independent PIM list for NSAIDs with the same advantages as observed for the STOOP and 2019 Beers criteria and recommended its use.
000168122 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000168122 588__ $$aDataset connected to CrossRef, PubMed,
000168122 650_7 $$2Other$$aNSAIDs
000168122 650_7 $$2Other$$aNon-Steroidal Anti-inflammatory Drugs
000168122 650_7 $$2Other$$aPain
000168122 650_7 $$2Other$$aPotentially Inappropriate Medication
000168122 650_7 $$2Other$$aSurvey
000168122 7001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aLaetsch, Dana Clarissa$$b1$$udkfz
000168122 7001_ $$0P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aChen, Li-Ju$$b2$$udkfz
000168122 7001_ $$0P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aHolleczek, Bernd$$b3$$udkfz
000168122 7001_ $$aMeid, Andreas D$$b4
000168122 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$udkfz
000168122 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b6$$eLast author$$udkfz
000168122 773__ $$0PERI:(DE-600)2023869-1$$a10.1093/pm/pnaa480$$gp. pnaa480$$n9$$p1962-1969$$tPain medicine$$v22$$x1526-4637$$y2021
000168122 909CO $$ooai:inrepo02.dkfz.de:168122$$pVDB
000168122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000168122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168122 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aExternal Institute$$b3$$kExtern
000168122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000168122 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000168122 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000168122 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000168122 9141_ $$y2021
000168122 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000168122 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPAIN MED : 2019$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000168122 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-30
000168122 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000168122 980__ $$ajournal
000168122 980__ $$aVDB
000168122 980__ $$aI:(DE-He78)C070-20160331
000168122 980__ $$aUNRESTRICTED